Posted by Michael Wonder on 28 Mar 2020
Highlights from the 23-26 March 2020 CHMP meeting
27 March 2020 - Eight new medicines recommended for approval.
EMA’s CHMP recommended eight medicines for approval at its March 2020 meeting. In line with EMA’s measures to limit the spread of COVID-19, the meeting was held virtually.
The Committee recommended granting a conditional marketing authorisation for Zolgensma (onasemnogene abeparvovec), an advanced therapy medicinal product for the treatment of babies and young children with spinal muscular atrophy, a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement.
